Armstrong N, Ryder S, Forbes C, et al. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543-561.
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†. Ann Oncol. 2020;S0923-7534(20)42460-42463. doi:10.1016/j.annonc.2020.09.010 [Epub ahead of print]
Daly MB, Pilarski R, Yurgelun MB, et al. NCCN Guidelines Insights: Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020. J Natl Compr Canc Netw. 2020;18:380-391.
Ducreux M, Cuhna A Sa, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v56-68.
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.
Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33:3124-3129.
Institut National du Cancer. The National Oncogenetics System. Updated July 1, 2020. Accessed October 27, 2020. https://www.e-cancer.fr/Professionnels-de-sante/L-organisation-de-l-offre-de-soins/Oncogenetique-et-plateformes-de-genetique-moleculaire/Le-dispositif-national-d-oncogenetique
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763.
Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-275.
Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31:377-386.
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533.
Singer CF, Balmaña J, Bürki N, et al. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer--an European consensus statement and expert recommendations. Eur J Cancer. 2019;106:54-60.
Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005;5:388-393.
Vidula N, Dubash T, Lawrence MS, et al. Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer. Clin Cancer Res. 2020;26:4852-4862.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Michel Ducreux, MD, PhD

Head, Gastrointestinal Unit
Institut Gustave Roussy
Villejuif, France
Professor of Oncology
Paris-Saclay University
Paris, France

Disclosures

Disclosure: Michel Ducreux, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Bayer; Ipsen; Merck Serono; Merck Sharpe & Dohme; Pierre Fabre; Roche; Servier
Served as a speaker or a member of a speakers bureau for: Amgen; Bayer; Ipsen; Merck Serono; Merck Sharp & Dohme; Pierre Fabre; Roche; Servier
Received grants for clinical research from: Bayer; Merck Serono; Roche
Other: Spouse is head of oncology business of Sandoz French Affiliate.

Fabrice André, MD, PhD

Director of Research
Department of Medical Oncology
Institut Gustave Roussy
Villejuif, France
Consultant Medical Oncologist
Professor of Medicine
Paris-Saclay University
Paris, France

Disclosures

Disclosure: Fabrice André, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Daiichi Sankyo; Eli Lilly; Genentech; Novartis; Pfizer; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Daiichi Sankyo; Eli Lilly; Genentech; Novartis; Pfizer; Roche
Received grants for clinical research from: AstraZeneca; Daiichi Sankyo; Eli Lilly; Genentech; Novartis; Pfizer; Roche
Owns stock, stock options, or bonds from: Pegacsy

Angela Lamarca, MD, PhD, MSc

Consultant in Medical Oncology
HPB-NET Team, Department of Medical Oncology
The Christie NHS Foundation Trust
Honorary Senior Lecturer
Division of Cancer Sciences
School of Medical Sciences
Faculty of Biology, Medicine and Health
University of Manchester
Manchester, United Kingdom

Disclosures

Disclosure: Angela Lamarca, MD, PhD, MSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: EISAI; Ipsen; Nutricia; QED; Roche
Served as a speaker or a member of a speakers bureau for: AAA; Incyte; Ipsen; Merck; Pfizer
Received grants for clinical research from: Roche
Other: AAA; Bayer; Delcath; Ipsen; Mylan; Novartis; Pfizer; Sirtex

Editors

Deborah Middleton, MS

Senior Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Yoji Yamaguchi, MA

Associate Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Yoji Yamaguchi, MA, has disclosed no relevant financial relationships.

CME/Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

The Evolution of Best Practices in BRCA Testing: Implications for Personalized Therapy in Breast and Pancreatic Cancers

Authors: Michel Ducreux, MD, PhD; Fabrice André, MD, PhD; Angela Lamarca, MD, PhD, MSc
CPD Released: 11/17/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 11/17/2021

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematologic and oncologic specialists and pathologists.

The goal of this activity is to improve the knowledge and confidence of oncologists and other healthcare providers who diagnose and treat breast and pancreatic cancers to utilize early testing for germline BRCA (gBRCA) in order to select the most appropriate therapeutic options for these patients.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Utility of BRCA testing in breast and/or pancreatic cancers
- Implications of early BRCA testing as a predictive biomarker for targeted therapies in breast and/or pancreatic tumors
Demonstrate greater competence in their ability to
- Select appropriate treatment options for patients with breast and/or pancreatic cancers

Disclosures

Faculty

Michel Ducreux, MD, PhD

Head, Gastrointestinal Unit
Institut Gustave Roussy
Villejuif, France
Professor of Oncology
Paris-Saclay University
Paris, France

Disclosures

Disclosure: Michel Ducreux, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Bayer; Ipsen; Merck Serono; Merck Sharpe & Dohme; Pierre Fabre; Roche; Servier
Served as a speaker or a member of a speakers bureau for: Amgen; Bayer; Ipsen; Merck Serono; Merck Sharp & Dohme; Pierre Fabre; Roche; Servier
Received grants for clinical research from: Bayer; Merck Serono; Roche
Other: Spouse is head of oncology business of Sandoz French Affiliate.

Fabrice André, MD, PhD

Director of Research
Department of Medical Oncology
Institut Gustave Roussy
Villejuif, France
Consultant Medical Oncologist
Professor of Medicine
Paris-Saclay University
Paris, France

Disclosures

Disclosure: Fabrice André, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Daiichi Sankyo; Eli Lilly; Genentech; Novartis; Pfizer; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Daiichi Sankyo; Eli Lilly; Genentech; Novartis; Pfizer; Roche
Received grants for clinical research from: AstraZeneca; Daiichi Sankyo; Eli Lilly; Genentech; Novartis; Pfizer; Roche
Owns stock, stock options, or bonds from: Pegacsy

Angela Lamarca, MD, PhD, MSc

Consultant in Medical Oncology
HPB-NET Team, Department of Medical Oncology
The Christie NHS Foundation Trust
Honorary Senior Lecturer
Division of Cancer Sciences
School of Medical Sciences
Faculty of Biology, Medicine and Health
University of Manchester
Manchester, United Kingdom

Disclosures

Disclosure: Angela Lamarca, MD, PhD, MSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: EISAI; Ipsen; Nutricia; QED; Roche
Served as a speaker or a member of a speakers bureau for: AAA; Incyte; Ipsen; Merck; Pfizer
Received grants for clinical research from: Roche
Other: AAA; Bayer; Delcath; Ipsen; Mylan; Novartis; Pfizer; Sirtex

Editors

Deborah Middleton, MS

Senior Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Yoji Yamaguchi, MA

Associate Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Yoji Yamaguchi, MA, has disclosed no relevant financial relationships.

CME/Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

The Evolution of Best Practices in BRCA Testing: Implications for Personalized Therapy in Breast and Pancreatic Cancers

Authors: Michel Ducreux, MD, PhD; Fabrice André, MD, PhD; Angela Lamarca, MD, PhD, MScFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CPD Released: 11/17/2020

Valid for credit through: 11/17/2021

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CPD Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Michel Ducreux, MD, PhD

Fabrice André, MD, PhD

Angela Lamarca, MD, PhD, MSc

Editors

Deborah Middleton, MS

Yoji Yamaguchi, MA

CME/Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CPD

The Evolution of Best Practices in BRCA Testing: Implications for Personalized Therapy in Breast and Pancreatic Cancers

Target Audience and Goal Statement

Disclosures

Faculty

Michel Ducreux, MD, PhD

Fabrice André, MD, PhD

Angela Lamarca, MD, PhD, MSc

Editors

Deborah Middleton, MS

Yoji Yamaguchi, MA

CME/Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Evolution of Best Practices in BRCA Testing: Implications for Personalized Therapy in Breast and Pancreatic Cancers

Educational Impact Challenge